Biocon Ltd. and Mylan NV on Thursday launched Ogivri, used for treatment of certain breast and stomach cancers, in Australia. It is a biosimilar of Hoffmann-La Roche's Herceptin.
Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme, Biocon and Mylan said in a joint statement.
"We are excited to enable access to Ogivri, in Australia, a high-quality biosimilar trastuzumab, co-developed and manufactured by Biocon,” said Christiane Hamacher, chief executive officer of Biocon Biologics. Commercialisation of Ogivri by Mylan, in Australia, extends the global footprint of biosimilar trastuzumab, she added.
"Mylan's investment in biosimilars is an exciting evolution in how we can treat Australian patients. We are delighted that Ogivri enables Mylan, with our partner Biocon, to bring this treatment option to Australian patients with HER2-positive breast and gastric cancers," Mylan Australia Country Manager Sylvain Vigneault said.
Mylan and Biocon's trastuzumab biosimilar is currently approved in more than 65 countries around the world, including the U.S., the statement said. The companies are exclusive partners on a broad portfolio of biosimilar and insulin products.
On Thursday, Biocon shares fell 1.37 percent to Rs 223.60 apiece on the BSE while the benchmark Sensex fell 1.23 percent to end the day at 37,018.32 points.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
